Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00385502
Other study ID # MCHM EC-200
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2006
Est. completion date June 2008

Study information

Verified date September 2020
Source Abeona Therapeutics, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 40 qualified subjects with mild-to-moderate great toenail fungus infection will be treated for 48 weeks with lacquer application to at least one affected great toenail. All subjects will receive treatment with EcoNail™ lacquer.


Description:

This study will use a multi-center, open-label study design in subjects with onychomycosis of at least one great toenail to assess the safety, local tolerability, and efficacy of chronic daily ungual application of EcoNail™. Forty (40) evaluable subjects will apply study drug daily to at least one affected great toenail for 48 weeks. The subjects must comply with all inclusion and exclusion criteria.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 2008
Est. primary completion date June 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subjects who are men and women greater than or equal to 18 years of age and less than or equal to 65 years of age.

- Female subjects who are post-menopausal (amenorrheic for at least 1 year), surgically sterile, have a partner with a vasectomy, or routinely using an acceptable means of contraception (acceptable methods may include hormonal contraceptives, intrauterine device, spermicide and barrier, abstinence and partner/spouse sterility).

- Subjects who have mycologically confirmed distal subungual onychomycosis of at least one or both great toenails ("target toenails"), defined as a positive result by office-based KOH preparation (± Chlorazol B) and by laboratory culture demonstrating one of more of the following organisms: T. rubrum, T. mentagrophytes, T. tonsurans and/or E. floccosum

- Subjects who have target toenail showing 20-65% (+/- 2%) involvement as judged by the clinical investigator.

- Subjects who have target toenail showing great than or equal to 3 mm distal involvement as judged by the clinical investigator.

- Subjects who have target toenail showing great than or equal to 2 mm proximal clear nail at the cuticle.

- Subjects must agree not to apply other nail polish or related products to the affected nails for the duration of the study.

- Subjects must refrain from filing, clipping, or otherwise disturbing the treated nail(s) for the duration of the study [NOTE: Clinic personnel will debride the affected nails during monthly visits. Subjects should not engage in these activities at home during the course of the study.]

- Subjects must have the ability to understand the nature of the study and any hazards of participating in it and the willingness to communicate satisfactorily with the investigator and staff and to participate in, and comply with the requirements of the entire study.

- Subjects must be able to read and sign the study Informed Consent form and comply with the requirements outlined in the informed consent form.

Exclusion Criteria:

- Subjects with < 20% or > 65% (+/- 2%) involvement of the target toenail.

- Subjects with great than or equal to 4 mm thickness of the target toenail.

- Subjects with totally dystrophic great toe.

- Subjects with great toenails which show white superficial or proximal subungual onychomycosis, or a "spike" of onychomycosis extending to the cuticle.

- Subjects whose nail cultures grow Candida species as the only pathogen.

- Subjects who have reported treatment with a topical anti-fungal agent for onychomycosis during the four weeks prior to screening for this study.

- Subjects who have been treated with a systemic anti-fungal agent during the three months prior to screening for this study.

- Subjects with any other nail abnormality or dermatological condition, including (but not limited to) psoriasis and lichen planus, that could prevent obtaining a normal-appearing toenail if complete cure was achieved or could otherwise interfere with required study assessments.

- Subjects with a history of organ transplantation, Human Immunodeficiency Virus (HIV) seropositivity or other historical or clinical evidence of an immunocompromised state.

- Subjects with a history of uncontrolled insulin-dependent diabetes mellitus.

- Subjects with a history of diabetic peripheral neuropathy.

- Subjects with a history of clinically significant lower extremity peripheral occlusive vascular disease.

- Subjects with a presence of plantar (moccasin) tinea pedis.

- Subjects with a history of hypersensitivity or allergic reactions on the skin or nails, including reactions to nail polish and/or nail polish remover.

- Subjects known to have an allergy to econazole, ethanol, Eudragit, or SEPA.

- Female subjects who are pregnant or lactating.

- Subjects with clinically relevant abnormal history, physical findings, or laboratory values at the screening assessment that could interfere with the objectives or the safety of the volunteer.

- Subjects who have a condition or abnormality that in the investigator's opinion may interfere with the assessments, conduct of the study, may affect the subject's safety, or is otherwise unsuitable for enrollment.

- Subjects who are currently participating or, within the previous 30 days, have participated in another investigational drug study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
nail lacquer applied daily for 48 weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Abeona Therapeutics, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine effectiveness of EcoNail™ lacquer, as determined by effects on nail mycology and appearance, when applied daily for 48 weeks to diseased great toenails in subjects with onychomycosis. Week 48
Secondary Evaluate the safety and local tolerability of EcoNail™ lacquer under the same circumstances. Week 56
See also
  Status Clinical Trial Phase
Completed NCT03098615 - Study Evaluating the Effect of Jublia on Dermatophytomas Phase 4
Recruiting NCT01666002 - Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser N/A
Terminated NCT01208129 - Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Phase 3
Terminated NCT01208168 - Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Phase 3
Completed NCT01180491 - A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis N/A
Completed NCT00253305 - Topical Gel Anti-Fungal Agent for Tinea Unguium Phase 2
Not yet recruiting NCT05809297 - Diode Laser and Photodynamic Therapy Vs. Ciclopirox. Phase 4
Completed NCT03405818 - An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Phase 4
Completed NCT02588599 - A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis N/A
Recruiting NCT02436291 - Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Phase 4
Completed NCT01851590 - Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Phase 4
Completed NCT01452490 - Diode Laser Treatment of Onychomycosis N/A
Withdrawn NCT00938925 - Effectiveness of Podiatry Care on Onychomycosis (EPOCAON) N/A
Recruiting NCT00808366 - Efficacy and Safety of RV4104A Ointment in Onychomycosis N/A
Completed NCT00781820 - Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste Phase 3
Completed NCT00768768 - Iontophoretic Application of Terbinafine Gel to the Large Toe Nail Phase 1
Completed NCT00777868 - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis Phase 2
Recruiting NCT06074315 - Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis N/A
Completed NCT01039883 - A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule Phase 1
Suspended NCT05491603 - A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis Phase 2

External Links